Axial Biotherapeutics, a Boston, MA-based company that harnesses the gut microbiome to treat patients with CNS disorders, raised $19.15m in Series A funding.
The round was led by Longwood Fund and Domain Associates with participation from Kairos Ventures, Heritage Medical Systems and a group of high net worth individuals based in Southern California.
Founded by Sarkis Mazmanian, Ph.D., Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders.
The company is leveraging the work of founder, Professor Mazmanian, which uses the gut microbiome to help treat diseases and disorders of the central nervous system (CNS).
Axial has licensed exclusive, worldwide rights to intellectual property which covers a novel and proprietary class of CNS biotherapeutics from the Mazmanian Laboratory at Caltech.
In conjunction with the financing, Axial Biotherapeutics announced the appointment of David H. Donabedian, Ph.D., as Chief Executive Officer and Board Director. Additional Axial Board members include, James C. Blair, Ph.D. Partner, Domain Associates, Michelle Dipp, M.D., Ph.D., Partner, Longwood Fund, and Mazmanian.